Fa Liu
Focus-X is a preclinical stage biotech company committed to the Discovery and development,, of personalized precision medicine fulfilling the unmet needs in cancer diagnosis and treatment. We are to release the true potential of radioligand therapy by leveraging our world class peptide drug discovery platform and joining force with top radiopharmaceutical partners.
Focus-X Therapuetics
CEOMr. Lei Liu
3E Bioventures Capital is dedicated to investing in cutting-edge life sciences and biomedical technologies, with a focus on breakthrough first-in-class therapies and disruptive cross-disciplinary innovations in medical devices and diagnostics.
3E Bioventures takes on a science-driven, entrepreneur-friendly investment philosophy by working closely with companies and research institutions to develop drugs or products that have strong unmet medical needs. With offices in Beijing, Shanghai, and the San Francisco Bay Area, 3E Bioventures leverages its experience, capabilities, and network to help companies tap into markets and resources across the Pacific and advance with greater speed and capital efficiency.
The motto of 3E Bioventures Capital is captured in its name 3E: Expertise, Efficiency, Execution.
3E Bioventures takes on a science-driven, entrepreneur-friendly investment philosophy by working closely with companies and research institutions to develop drugs or products that have strong unmet medical needs. With offices in Beijing, Shanghai, and the San Francisco Bay Area, 3E Bioventures leverages its experience, capabilities, and network to help companies tap into markets and resources across the Pacific and advance with greater speed and capital efficiency.
The motto of 3E Bioventures Capital is captured in its name 3E: Expertise, Efficiency, Execution.
3E BioVentures
DirectorMs. Annie Liu
Founded in 2016 with over $800 million assets under management, Terra Magnum Capital Partners ("TMCP" or "the firm") is a China-focused private equity firm specialized in both direct investments and fund investments.
Terra Magnum Capital
Analyst![AnHeart Therapeutics Organisation logo](/media/orglogo/2815/org/344247.png)
Dr. Akira Liu
AnHeart Therapeutics is an oncology-focused clinical stage biopharmaceutical company headquartered in Hangzhou, China with offices in Beijing, Shanghai and New York. The company’s pipeline consists of three clinical stage assets: Taletrectinib, a next-gen ROS1 and NTRK inhibitor currently in Phase 2; an mIDH1 inhibitor ready for Phase 2 for low grade glioma, cholangiocarcinoma, AML and other tumors; and an AXL inhibitor in Phase 1 for overcoming resistance in various tumors.